Bionano Genomics, Inc.
1.8200-0.05 (-2.67%)
Oct 29, 4:00:01 PM EDT · NasdaqCM · BNGO · USD
Key Stats
Market Cap
17.62MP/E (TTM)
-Basic EPS (TTM)
-43.87Dividend Yield
0%Recent Filings
8-K
Q2 revenue dips, margins soar
Bionano Genomics reported Q2 2025 revenue of $6.7 million, down 13% from $7.8 million in Q2 2024 due to discontinued clinical services and fewer instrument sales, yet consumables and software rose 16% as routine OGM users drove growth. Gross margin surged to 52% from 33%, while operating expenses dropped 42% to $11.3 million, bolstering cash to $27.4 million. The strategy shift pays off. Company guides full-year revenue at $26-30 million and Q3 at $6.7-7.2 million, with cash lasting into Q1 2026 amid financing risks.
10-Q
Q2 FY2025 results
Bionano Genomics narrowed its Q2 FY2025 losses to $6.9M from $16.2M y/y, with revenue dipping 13% y/y to $6.7M on softer instrument sales but consumables up 28% y/y; gross margin expanded to 52% from 33% y/y, while operating expenses plunged 42% y/y to $11.3M, reflecting restructuring gains. For H1 FY2025, net loss shrank 79% y/y to $10.0M on $13.2M revenue (down 20% y/y), with diluted EPS improving to $(3.24) from $(47.50) on 3.1M weighted shares (derived). Cash burn eased to $6.3M from operations, ending with $3.6M cash, $12.9M short-term investments, and $11.0M restricted; $12.1M principal remains on 11% debentures due 2026, with $7.4M redemptions due in 2025. Extended HQ lease to 2030, but going concern doubts persist amid funding needs. Regulatory hurdles in diagnostics loom large.
8-K
Audit appointment and meeting approvals
Bionano Genomics bolstered its Audit Committee on June 10, 2025, by appointing Kristiina Vuori, M.D., Ph.D., enhancing oversight amid ongoing growth. At the June 11 annual meeting, with 47.82% turnout, shareholders elected R. Erik Holmlin and David Barker as Class I directors through 2028, approved executive pay advisory, ratified BDO USA as auditors, and greenlit 661,374 warrant shares for Nasdaq compliance. This strengthens governance while securing capital flexibility.
8-K
Bionano Q1 revenue dips, margins rise
Bionano Genomics reported Q1 2025 revenue of $6.5 million, down 26% from $8.8 million in Q1 2024, mainly due to discontinued clinical services and lower instrument sales, yet gross margin climbed to 46% from 32% amid cost cuts. Flowcell sales to routine OGM users held steady with 82% of total volume, while the installed base grew 9% year-over-year to 379 systems. Cash stood at $29.2 million, extending runway into Q1 2026. Publications bolster OGM's role in cytogenomics.
10-Q
Q1 FY2025 results
Bionano Genomics posted Q1 revenue of $6.5M, down 26% y/y from $8.8M, as product sales dipped 12% to $6.0M amid a strategic pivot to maximizing utilization of its 379 installed OGM systems, while service revenue cratered 77% after phasing out certain diagnostic offerings. Gross margin climbed to 46% from 32%, fueled by lower costs and restructuring gains, narrowing the operating loss to $8.5M from $31.1M; net loss shrank to $3.1M or $(1.15) per share on 2.7M diluted shares, versus $31.4M or $(35.75) on 0.9M shares last year. Cash burn eased to $2.8M from operations, ending with $3.6M in cash and $14.6M in short-term investments, though $11.0M remains restricted for $13.6M in debentures maturing 2026 at 11% interest. Equity raises added $13.3M net, bolstering liquidity into Q1 2026. Restructuring slashed headcount by over 200 since 2023, trimming R&D 76% and SG&A 53% y/y. Yet regulatory hurdles for clinical adoption loom large.
IPO
Website
Employees
Sector
Industry
AZTA
Azenta, Inc.
29.79-1.57
BDX
Becton, Dickinson and Company
181.52-2.69
IDXG
Interpace Biosciences, Inc.
1.10-0.04
ILMN
Illumina, Inc.
95.03-2.77
NEO
NeoGenomics, Inc.
10.28+0.36
NTRA
Natera, Inc.
192.81+3.24
QGEN
Qiagen N.V.
47.19-0.76
TWST
Twist Bioscience Corporation
32.21-1.36
TXG
10x Genomics, Inc.
12.90-0.44
WGS
GeneDx Holdings Corp.
131.76-5.71